secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001854270-23-000125
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio Q3 net loss $14.9M; cash $39.4M; Celest partnership up to $156M
-------------------------------------------------------------------------

- Net loss $14.9M ($0.34/share) includes non-recurring $21.7M gain and $25.7M impairment from GeneFab transaction.
- Cash and short-term investments $39.4M; expects to fund operations into Q4 2024.
- SENTI-202 IND on track for clearance Q4 2023; Phase 1 trial for AML expected to start early 2024.
- Celest collaboration for SENTI-301A: up to $156M milestones plus tiered royalties; first patient H1 2024 in China.
- GeneFab transaction: $37.8M total consideration; $18.9M at closing, $18.9M in installments 2024-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000125/0001854270-23-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000125/snti-20231113.htm
  HTML page:      https://secwatch.observer/filing/0001854270-23-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer